文献速递肝胆胰外科围术期管理与 ERAS

北美胰腺手术优化进展:2013-2017年趋势分析

Optimal Pancreatic Surgery: Are We Making Progress in North America?
PubMed 文献 · Ann Surg · 2021-01-01

该研究基于ACS NSQIP 2013-2017年数据,分析胰十二指肠切除术(PD,N=16222)和远端胰腺切除术(DP,N=7946)的管理趋势。结果显示总体并发症、死亡率和术后住院时间下降,最佳胰腺手术率在PD从53.7%升至56.9%,DP从53.3%升至58.5%。

要点

  • 最佳胰腺手术率PD从53.7%升至56.9%,DP从53.3%升至58.5%。
  • 机器人PD增加(2.5%至4.2%),腹腔镜PD减少(5.8%至4.3%)。
  • 总体并发症、死亡率和术后住院时间均下降。

核心结论

  • 2013至2017年间,北美胰腺切除术的围术期流程得到优化,多种术后结局改善,最佳胰腺手术率增加3%至5%。

研究设计与样本

  • 回顾性队列研究,使用ACS NSQIP 2013-2017年参与者使用文件,纳入PD患者16222例和DP患者7946例。

主要发现

  • 机器人PD从2.5%增至4.2%(P<0.001),腹腔镜PD从5.8%降至4.3%(P<0.02)。
  • 手术时间减少(P<0.05),输血减少(P<0.001)。
  • 术后第1天引流液淀粉酶检查比例增加(P<0.001),术后第3天引流管拔除比例增加(P<0.001)。
  • 总体并发症(P<0.02)、死亡率(P<0.05)和术后住院时间(P=0.002)下降。
  • 最佳胰腺手术率PD从53.7%升至56.9%(P<0.01),DP从53.3%升至58.5%(P<0.001),胰腺癌患者亦然(P<0.01)。

关键数值与推荐

  • 最佳胰腺手术定义为无术后死亡、无严重并发症、无经皮穿刺引流、无再手术,且住院时间≤第75百分位(PD为12天,DP为7天),无再入院。

临床怎么用

  • 临床可参考最佳胰腺手术的复合指标评估手术质量,关注围术期流程优化如早期引流管拔除和淀粉酶检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our aims were to assess North American trends in the management of patients undergoing pancreatoduodenectomy (PD) and distal pancreatectomy (DP), and to quantify the delivery of optimal pancreatic surgery. BACKGROUND: Morbidity after pancreatectomy remains unacceptably high. Recent literature suggests that composite measures may more accurately define surgical quality. METHODS: The 2013 to 2017 American College of Surgeons National Surgical Quality Improvement Program Participant Use Files were queried to identify patients undergoing PD (N = 16,222) and DP (N = 7946). Patient, process, procedure, and 30-day postoperative outcome variables were analyzed over time. Optimal pancreatic surgery was defined as the absence of postoperative mortality, serious morbidity, percutaneous drainage, and reoperation while achieving a length of stay equal to or less than the 75th percentile (12 days for PD and 7 days for DP) with no readmissions. Risk-adjusted time-trend analyses were performed using logistic regression, and the threshold for statistical significance was P ≤ 0.05. RESULTS: The use of minimally invasive PD did not change over time, but robotic PD increased (2.5 to 4.2%; P < 0.001) and laparoscopic PD decreased (5.8% to 4.3%; P < 0.02). Operative times decreased (P < 0.05) and fewer transfusions were administered (P < 0.001). The percentage of patients with a drain fluid amylase checked on postoperative day 1 increased (P < 0.001), and a greater percentage of surgical drains were removed by postoperative day 3 (P < 0.001). Overall morbidity (P < 0.02), mortality (P < 0.05), and postoperative length of stay (P = 0.002) decreased. Finally, the rate of optimal pancreatic surgery increased for PD (53.7% to 56.9%; P < 0.01) and DP (53.3% to 58.5%; P < 0.001), and alspo for patients with pancreatic cancer (P < 0.01). CONCLUSIONS: From 2013 to 2017, pre, intra, and perioperative pancreatectomy processes have evolved, and multiple postoperative outcomes have improved. Thus, in 4 years, optimal pancreatic surgery in North America has increased by 3% to 5%.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Beane JD, Borrebach JD, Zureikat AH, et al. Optimal Pancreatic Surgery: Are We Making Progress in North America? Ann Surg. 2021. PMID: 31663969. doi:10.1097/SLA.0000000000003628

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。